Your browser doesn't support javascript.
loading
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Branche, Angela R; Rouphael, Nadine G; Losada, Cecilia; Baden, Lindsey R; Anderson, Evan J; Luetkemeyer, Anne F; Diemert, David J; Winokur, Patricia L; Presti, Rachel M; Kottkamp, Angelica C; Falsey, Ann R; Frey, Sharon E; Rupp, Richard; Bäcker, Martín; Novak, Richard M; Walter, Emmanuel B; Jackson, Lisa A; Little, Susan J; Immergluck, Lilly C; Mahgoub, Siham M; Whitaker, Jennifer A; Babu, Tara M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Netzl, Antonia; Smith, Derek J; Telu, Kalyani; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe K; Crandon, Sonja; Montefiori, David C; Roberts, Paul C; Beigel, John H.
Afiliação
  • Branche AR; Department of Medicine, University of Rochester VTEU, Rochester, New York, USA.
  • Rouphael NG; Department of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
  • Losada C; Department of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
  • Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Anderson EJ; Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia, USA.
  • Luetkemeyer AF; Zuckerberg San Francisco General, University of California San Francisco, San Francisco, California, USA.
  • Diemert DJ; George Washington Vaccine Research Unit, George Washington University, Washington DC, USA.
  • Winokur PL; Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
  • Presti RM; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Kottkamp AC; Department of Medicine, New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) Manhattan Research Clinic at NYU Grossman School of Medicine, New York, New York, USA.
  • Falsey AR; Department of Medicine, University of Rochester VTEU, Rochester, New York, USA.
  • Frey SE; Saint Louis University, Center for Vaccine Development, St. Louis, Missouri, USA.
  • Rupp R; Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
  • Bäcker M; Department of Medicine, NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, New York, USA.
  • Novak RM; Department of Medicine, University of Illinois at Chicago-Project WISH, Chicago, Illinois, USA.
  • Walter EB; Department of Pediatrics, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
  • Little SJ; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
  • Immergluck LC; Department of Microbiology/Biochemistry/Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
  • Mahgoub SM; Department of Medicine, Howard University College of Medicine, Howard University Hospital, Washington DC, USA.
  • Whitaker JA; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Babu TM; Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Goepfert PA; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Fusco DN; Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Atmar RL; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Posavad CM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Netzl A; Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
  • Smith DJ; Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
  • Telu K; The Emmes Company, LLC, Rockville, Maryland, USA.
  • Mu J; The Emmes Company, LLC, Rockville, Maryland, USA.
  • Makowski M; The Emmes Company, LLC, Rockville, Maryland, USA.
  • Makhene MK; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Crandon S; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Montefiori DC; Department of Surgery, Duke University, Durham, North Carolina, USA.
  • Roberts PC; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Beigel JH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Clin Infect Dis ; 77(4): 560-564, 2023 08 22.
Article em En | MEDLINE | ID: mdl-37036397
ABSTRACT
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos